Nausea or Vomiting in Patients Who Are Receiving Chemotherapy for Breast Cancer or Lung Cancer

NCT00416689 | Completed

• 3 other identifiers: CALGB-309801U10CA031946CDR0000460041
• Study Type: observational
• Target: 99
• Locations: 0 countries
• Sites: N/A

Brief Summary

RATIONALE: Understanding how nausea or vomiting caused by chemotherapy effects a patient's treatment decisions may help doctors plan better cancer treatment and may help patients live more comfortably. PURPOSE: This clinical trial is studying nausea or vomiting in patients who are receiving chemotherapy for breast cancer or lung cancer.

Conditions

Breast Cancer; Lung Cancer; Nausea and Vomiting

Keywords

nausea and vomiting; pulmonary carcinoid tumor; recurrent breast cancer; stage I breast cancer; stage II breast cancer; stage IIIA breast cancer; stage IIIB breast cancer; stage IIIC breast cancer; stage IV breast cancer; recurrent non-small cell lung cancer; stage I non-small cell lung cancer; stage II non-small cell lung cancer; stage IIIA non-small cell lung cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer; extensive stage small cell lung cancer; limited stage small cell lung cancer; recurrent small cell lung cancer

Study Arms (1)

Breast or lung CA pt undergoing chemoTx

Procedure: assessment of therapy complications; Procedure: quality-of-life assessment

Interventions

assessment of therapy complications PROCEDURE

Breast or lung CA pt undergoing chemoTx

quality-of-life assessment PROCEDURE

Breast or lung CA pt undergoing chemoTx

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Breast or lung cancer patients undergoing chemotherapy

DISEASE CHARACTERISTICS: * Diagnosis of breast cancer or lung cancer * Must be undergoing chemotherapy with each course lasting 3-6 weeks AND meets all of the following criteria: * Completed ≥ 1 course with ≥ 1 additional course planned * At least 2½ weeks since initiation of the most recent course of chemotherapy PATIENT CHARACTERISTICS: * Common Toxicity Criteria performance status 0-2 * Must have command of written and/or spoken English PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Alliance for Clinical Trials in Oncology: lead
• National Cancer Institute (NCI): collaborator

MeSH Terms

Conditions

Breast Neoplasms; Lung Neoplasms; Nausea; Vomiting; Carcinoma, Non-Small-Cell Lung; Small Cell Lung Carcinoma

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Diseases; Respiratory Tract Diseases; Signs and Symptoms, Digestive; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Carcinoma, Bronchogenic; Bronchial Neoplasms

Study Officials

• Steven Grunberg, MD

  University of Vermont Medical Center

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 27, 2006
• First Posted: December 28, 2006
• Study Start: April 1, 2000
• Primary Completion: March 1, 2003
• Study Completion: January 1, 2006
• Last Updated: June 29, 2016

Record last verified: 2016-06